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ABSTRACT: The bifunctional enzyme N5,N10-methylenetetrahydrofolate dehydrogenase/cyclo hydrolase (FolD) is essential
for growth in Trypanosomatidae. We sought to develop inhibitors of Trypanosoma brucei FolD (TbFolD) as potential
antiparasitic agents. Compound 2 was synthesized, and the molecular structure was unequivocally assigned through X-ray
crystallography of the intermediate compound 3. Compound 2 showed an IC50 of 2.2 μM, against TbFolD and displayed
antiparasitic activity against T. brucei (IC50 49 μM). Using compound 2, we were able to obtain the ﬁrst X-ray structure of
TbFolD in the presence of NADP+ and the inhibitor, which then guided the rational design of a new series of potent TbFolD
inhibitors.
■ INTRODUCTION
Kinetoplastidae are ﬂagellated protozoan parasites, including
serious human pathogens that are transmitted by diﬀerent
insect vectors. Diseases caused by kinetoplastids include human
African trypanosomiasis (HAT, also known as African sleeping
sickness), which is due to infection with Trypanosoma brucei
gambiense or T. brucei rhodesiense; Chagas disease, which is
caused by T. cruzi; and various forms of leishmaniasis caused by
infection with diﬀerent species of Leishmania.1 Those living in
tropical and subtropical areas of the world are at risk of
contracting these diseases. Sleeping sickness, which is found
predominantly across sub-Saharan Africa, is fatal if not treated,
and all drugs used in the treatment of HAT have issues relating
to eﬃcacy, administration, and side eﬀects. Additionally,
increasing levels of drug resistance2 demonstrate the need for
new, improved, and aﬀordable drugs. We have previously
identiﬁed the bifunctional enzyme FolD as an interesting target
for antibacterial drug discovery.3 This enzyme produces N10-
formyl-tetrahydrofolate (THF) in a two-step reaction. First,
N5,N10-methylene-THF is converted to N5,N10-methenyl-THF
by the NADP+ or NAD+-dependent N5,N10-methylene-THF
dehydrogenase (DH); then, N10-formyl-THF is produced by
the action of N5,N10-methenyl-THF cyclohydrolase (CH,
Figure 1).
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FolD crystal structures have been reported from diﬀerent
organisms,3−7 including Leishmania major8 but not from T.
brucei. We initiated an inhibitor discovery program targeting the
T. brucei enzyme (TbFolD) and selected as a lead compound
Figure 1. Proposed reaction mechanism of TbFolD.
Figure 2. (A) Structures of 1 and 2; (B) Molecular formula of one symmetry-independent molecule of intermediate 3 and of the DMSO unit
showing the atom numbering scheme.
Scheme 1. Synthesis of Compounds 2−5
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LY374571 (compound 1) developed by Eli Lilly and Company
because it inhibits bacterial and human FolD.9 However,
following the protocol reported for the synthesis of 1, we
obtained a new compound whose structure has been
unambiguously determined as 2 (Figure 2). We judge it likely
that the original report refers to compound 2 not 1. To conﬁrm
2 as a suitable lead compound for the development of TbFolD
inhibitors, we submitted it to biological evaluation against
recombinant TbFolD. Using compound 2, we were able to
obtain the ﬁrst X-ray structure of TbFolD in the presence of
NADP+ and the inhibitor. The X-ray crystal structure of the
complex TbFolD-2-NADP+ revealed molecular details that
were relevant to the binding and inhibition of the enzyme, and
allowed, with the help of molecular modeling, a rational design
of several analogues (compounds 16−20). Multiple sequence
alignment of FolD from several diﬀerent organisms (see Figure
S1) and superimposition of the corresponding three-dimen-
sional structures provided insight into the major determinants
of ligand binding and selectivity for the diﬀerent FolD forms
(see Figure S2). Antiparasitic activity against the bloodstream
form of T. brucei and cytotoxicity against human leukemia
macrophages, diﬀerentiated from THP1 monocytes, were
evaluated for all compounds under study.
■ RESULTS
Synthetic Chemistry. Compound 2 was prepared
following a procedure5 originally reported to aﬀord 1 (Figure
2). However, in contrast to what was reported by Schmidt et
al.5 reaction of 4-hydroxy-2,5,6-triaminopyrimidine sulfate with
ethyl 4-isocyanatobenzoate (Scheme 1) aﬀorded a derivative
with the urea moiety linked at position 5 (compound 3) instead
of position 6. Our structural assignment is based on the X-ray
analysis of 3, which was crystallized as a thin plate by slow
evaporation from dimethyl sulfoxide (DMSO). This result
provides an important veriﬁcation of the chemical structure of
2. Figure 2B shows the molecular formula of one symmetry-
independent molecule of 3 with DMSO and the atom
numbering scheme (see Supporting Information for details
on crystal determination: Figure S3, S4, and S5). CCDC
973826 contains the full supplementary crystallographic data.
The latter can be obtained free of charge from the Cambridge
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_
request/cif. This structural assignment is in agreement with
data reported by Eadsforth et al. dealing with the crystallo-
graphic analysis of an Acinetobacter baumanii FolD ligand
complex.9
A series of new analogues of compound 2 were designed on
the basis of the crystallographic data and molecular modeling
studies, as discussed in detail later. As shown in Scheme 1
intermediate 4 was reacted with a series of diﬀerent α-amino
acids 6−9 or with γ-amino butyric acid 10, all as methyl esters,
using N-methylmorpholine and 2-chloro-4,6-dimethoxy-1,3,5-
triazine as coupling reagents, aﬀording derivatives 11−15,
which were ﬁnally converted into the desired compounds 16−
20 by alkaline hydrolysis with 1 N NaOH (Scheme 2).
Single Crystal X-ray Diﬀraction Analysis of 3. The
molecular structure of 3, as obtained from X-ray diﬀraction
analysis, is shown in Figure S3. The asymmetric unit consists of
four independent molecules (labeled A, B, C, and D), each of
them being strictly associated with a DMSO host molecule
(called E, F, G, and H); see Figure S4. Therefore, the unit cell
contains a total of 8 3/DMSO adducts. The four unique
molecule 3 entities mainly diﬀer by the torsion angles τ
between the pyrimidine ring and the ureic moieties (Table S1).
In general, the pyrimidine ring is almost perpendicular to the
phenyl mean plane, whereas the ureic group roughly lies in the
same plane as the phenyl system. For example, the τ(O3-C10-
N1-C7) angle is as low as 6(2), 0(2), −2(2) and 7(2) degrees
in molecules A, B, C, and D, respectively.
As for the crystal packing, A/B and C/D alternating pairs of
closely associated independent molecules are arranged along
the [ 1 ̅10 ] axis (Figure S5a). Within each pair, a cyclic network
of N3−H3···O4 hydrogen-bonded contacts is set up between
almost coplanar facing pyrimidine rings (Figure S5b). The
other pyrimidinic nitrogen (N4) acts as an acceptor of an
intermolecular hydrogen bond donated from the −N6H2 group
(Figure S5c), determining the formation of two symmetry-
independent inﬁnite hydrogen-bonded zigzag ribbons in the
(110) plane (Figure S5a). Moreover, the ureic system is
involved in hydrogen-bonded contacts with the oxygen of the
cocrystallized solvent, whereas the O3 oxygen is a hydrogen-
bond acceptor interacting with a neighboring −N5H2 group.
Table S2 summarizes all the relevant intermolecular hydrogen-
bonded contacts in crystalline 3.
Crystal Structure of the Ternary TbFolD Inhibitor
Complex. The preparation of an eﬃcient recombinant
Scheme 2. Synthesis of Compounds 16−20
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Escherichia coli protein production system as well as the
puriﬁcation, crystallization, and structure determination of
TbFolD in a ternary complex with NADP+ and the inhibitor
(S)-2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydro pyrimidin-5-yl)
ureido)benzamido) pentanedioic acid (2) is detailed in the
Supporting Information. The structure was determined to 2.05
Å resolution. The inhibitor and ADP component of the
cofactor were clearly deﬁned by the high-resolution electron
density, but the density was less well ordered for the nicotinate
moiety.
The TbFolD subunit, which is a polypeptide of 297 amino
acids, displays a distinctive tertiary structure typical of this
enzyme family. This subunit consists of 11 α-helices and 11 β-
strands forming a two-domain structure.4 TbFolD forms a
dimer in solution, as shown by size exclusion chromatography,
and a dimer constitutes the asymmetric unit of the crystal
structure. Approximately 10% of a subunit surface is occluded
from the solvent by dimer formation. The C-terminal domain
displays the Rossmann fold and binds NADP+ in a deep cleft.
The adenine occupies a hydrophobic pocket near the surface of
the enzyme, and the nicotinate is then located between the C-
and N-terminal domains. The amino acids that form the
cofactor-binding site and interact with the cofactor are highly
conserved.9 We previously noted in diﬀerent crystal structures
of bacterial FolD that the conformation of a loop adjacent to
the active site, the β8-α10 loop, was variable. The loop occludes
the active site in the structure of the Pseudomonas aeruginosa
FolD (PaFolD). In the case of the TbFolD, the loop adopts an
open conﬁguration, lining and helping to create the active site
(Figure S6).
The folate-binding catalytic center is a deep, solvent-ﬁlled
cavity on the N-terminal domain. Here, 2 binds with an
extended conformation (Figure 3). The pyrimidine headgroup
is wedged between K56 and Q100 on one side and I174 (not
shown) on the other. The K56 and Q100 side chains are linked
together by a hydrogen bond. Direct hydrogen bonding
interactions between the inhibitor headgroup and the enzyme
involve the side chain of D123, the main chain carbonyls of
L101 and V99, and the main chain amide of L101. Additionally,
a number of solvent-mediated interactions link 2 O4 to the side
chains of K56 and D123. The K56 side chain also binds to the
carbonyl group of the linking amide. The 2 benzyl forms π-
stacking interactions on one side with Y52; on the other side,
there are van der Waals interactions with G276, P277, and
T279. The α-carboxylate group of the ligand glutamate moiety
participates in a direct charge-reinforced hydrogen bond with
the G273 main chain nitrogen and a long-range ionic
interaction with the side chain of R10. In similar fashion, the
γ-carboxylate interacts with R54. In addition, there are several
solvent-mediated interactions that link these acidic groups to
G274, G276, and Y250. The side chains of T51, L55, and L252
together with P272 form a hydrophobic clamp to position the
tail of the inhibitor.
Molecular Design, Enzyme Inhibition, and SAR Study.
Compound 2 was tested for the inhibition of FolD
dehydrogenase activity using an established assay.3 To enlarge
the SAR study, we decided to include in the panel of
compounds under evaluation also the synthetic intermediates
3−5. The biological data are reported in Table 1. We selected
compound LY354899 (21), a competitive inhibitor of the
human (Ki 29 nM), Pseudomonas aeruginosa (30 nM) and L.
major (105 nM) FolD enzymes,8,9 as a reference compound,
whose structure represents a rigid cyclized analogue of
compound 2. Superimposition of the available A. baumanii
FolD/21 structure (PDB code 4V4V) on the TbFolD/2
complex, herein described, shows that the two ligands adopt the
same binding conformation (Figure S7 in Supporting
Information). In accordance, compound 21 displayed TbFolD
inhibitory activity with a Ki comparable to that of compound 2
(Ki = 8.5 μM and 1.1 μM, respectively).
In stark contrast, the inactivity or very low level of inhibition
observed with compounds 3−5 conﬁrms that the aforemen-
tioned interactions displayed by the glutamate tail are essential
for the inhibitory activity. Indeed, both the elimination of the
glutamate portion (compounds 3−4) and the esteriﬁcation of
the γ-carboxylate group (compound 5) led to a signiﬁcant drop
in the inhibitory properties of these compounds.
On the basis of the TbFolD/2/NADP+ ternary complex
presented here, new compounds 16−20 were designed,
synthesized, and tested in an enzyme assay. Speciﬁcally,
compounds 18 and 19 were designed to ﬁll the hydrophobic
cleft formed by the side chains of Y52, Y250, L252, and T51.
Indeed, derivative 18 (Ki = 0.54 μM) displayed a 2-fold increase
of the inhibitory potency, compared to that of compound 2. In
contrast, the lower activity of 19 suggests that the hydroxyl
group on the terminal phenyl ring is not well accepted,
probably due to its electron-donating properties that
unfavorably aﬀect the π−π interaction with Y52 and Y250.
We considered that a direct interaction with R54 would be
beneﬁcial for inhibition, and compound 16 (Ki = 0.48 μM) was
designed for that purpose. The 2-fold increase in the inhibitory
potency of this compound, compared to that of compound 2,
seems to conﬁrm our hypothesis.
However, compounds 17 and 20 were synthesized as proof-
of-concept for the importance of the Cγ and Cα carboxylate
groups, respectively. Both derivatives showed a decreased
inhibitory potency, conﬁrming, once again, that at least two
strong interactions should be established by the amino acidic
tail in order to achieve submicromolar inhibition, either one
charge-reinforced H-bond and one ionic interaction, as for
compounds 2 and 16, or one charge-reinforced H-bond and
one hydrophobic interaction, as in the case of compound 18.
Figure 3. Compound 2 bound in the active site of TbFolD. The
polypeptide is depicted as oﬀ-white ribbon, the interacting residues,
and the nicotinate moiety of the cofactor, which was modeled, are
represented with C atoms as orange sticks, the ligand as cyan sticks. All
O, N, and H atom positions are red, blue, and white, respectively. Blue
dashed lines represent potential hydrogen bonding interactions.
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Molecular Docking. Potential binding poses of 16 and 18,
the most potent inhibitors identiﬁed in this series, were
calculated by means of Glide 5.5 software in extra precision
(XP) mode, using Glidescore for ligand ranking (see below). As
shown in Figure 4, the elongation of the γ-carboxylate chain
(16 vs 2) allows for a salt bridge interaction with the side chains
of R54 or R10. Speciﬁcally, in the TbFolD-2-NADP+ X-ray
structure the shortest distance between the 2 carboxylate
oxygen and an R54 guanidine hydrogen was around 5 Å, while
in the docking-derived pose the same distance is reduced to 2.6
Å. This direct and by implication stronger association is likely
the reason for the 2-fold increase in inhibitory potency of 16
with respect to 2.
Compound 18 was originally designed to ﬁll the hydrophobic
pocket shaped by the three residues Y52, Y250, and L252
residues. Indeed, two favored binding poses have been found,
one in which the phenyl ring occupies the above-mentioned
hydrophobic cleft forming a T-shaping assembly with the two
tyrosine residue side chains (see Figure 4) and another in
which the ligand phenyl group is directed toward R10
establishing a cation-π interaction (data not shown). However,
the lower activity of 19 would perhaps suggest that the latter
pose may not be relevant but would support the interaction of
the terminal phenyl ring with Y52 and Y25. These latter
interactions could be, in turn, the reason for the increased
inhibitory potency of 18 with respect to 2.
Comparison between Human and T. brucei FolD
Structures. Superimposition of the three-dimensional X-ray
structures of human and TbFolDs5 demonstrates that the
enzyme presents a similar structure in these two diverse species
Table 1. Summary of Compounds’ Activity
aμM. bIn vitro growth inhibition expressed as IC50 (μM) of all compounds against the T. brucei bloodstream form and human THP1 diﬀerentiated
macrophages. dPentamidine is the compound of reference (IC50 1.6 ± 0.2 nM).
dSelectivity index SI = IC50THP/IC50 T. brucei. NI = no inhibition.
Compound structures, enzyme inhibition, antiparasitic activity, and human macrophage growth inhibition are reported.
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and that the amino acids lining the active sites are overall well
conserved (Figure S2, overall sequence identity of 40%).
Nevertheless, a number of residues diﬀer between the two
enzymes, and a close inspection of the diﬀerent residues lining
the active sites reveals structural diﬀerences that could be
exploited for the discovery of new trypanocidal agents endowed
with low activity against the human FolD. Speciﬁcally, in
human FolD, residues K10, L51, N54, V55, K175, C236, and
I238 are replaced by R10, T51, R54, L55, D173, V236, and
T238, respectively, in TbFolD (Figure 5). The lysine−
arginine−asparagine−arginine diﬀerences at positions 10 and
54 might be targeted to achieve selectivity in inhibitor−enzyme
recognition and binding. Both TbFolD R10 and R54 are in
close proximity to the glutamate tail of 2 and may be reached
via appropriate modiﬁcation of the ligand’s glutamate residue.
Thus, the crystal structure of the TbFolD-2-NADP+ ternary
complex and comparison with the human FolD structure may
help address the challenging problem of how to achieve both
potency and selectivity toward the parasite and not the human
enzyme.
Antiparasitic Activity. All compounds were screened
against the bloodstream form of T. brucei and showed in vitro
dose-dependent killing, as determined from the reduction of
the resazurin marker for cell viability (Table 1). Despite the fact
that several compounds within this series showed a micromolar
or even submicromolar activity against the target enzyme
TbFolD, they did not display any remarkable antiparasitic
activity. Only compounds 2−5 showed a moderate antiparasitic
activity, and 2 was the most active, with an IC50 value of 49 ±
3.2 μM. The reference compound, analogue 21, exhibited a
similar activity. The remaining compounds were inactive. All
compounds were less active than suramin, a standard drug used
in HAT therapy. A counter-screen testing all compounds with
human macrophages diﬀerentiated from THP1 monocytes
showed more eﬀective toxic activity on the parasite than in
mammalian cells. Compounds 2, 5, and 21 were 4-, 2.2-, and
1.8-fold more eﬀective, respectively, against the T. brucei
bloodstream form than against that from human macrophages.
■ CONCLUSIONS
We have reported the ﬁrst crystal structure of TbFolD, a
potential therapeutic target, with the bonus of obtaining
information on the molecular basis of inhibition by compound
2. This molecule displays a micromolar enzyme inhibitory
activity against TbFolD and modest antiparasitic properties. A
key part of the analysis was the clear assignment of the
molecular structure of 2 using single crystal X-ray analysis of a
synthetic intermediate, 3. The crystal structure of the enzyme−
ligand complex provides an accurate template to support
structure-based approaches in early stage drug discovery. In
addition, we have suggested that, although FolD is a highly
conserved enzyme, as indicated by the primary sequence
alignment and structural comparisons, some critical diﬀerences
in the active sites could be exploited to reduce the activity on
the human form of the enzyme, and this possibility will be
pursued in future development of this class of compounds.
Moreover, because molecular recognition is a dynamic
process,10 diﬀerences in structural ﬂexibility between the
human and T. brucei enzymes might provide additional
information to support this eﬀort. Despite the fact that almost
all compounds showed low micromolar or submicromolar
inhibition of TbFolD, the antiparasitic activity on the
bloodstream form parasite was modest. Considering the polar
nature of these molecules, an explanation for the modest level
of antiparasitic activity is that structural modiﬁcation of the
amino acidic tail, while facilitating a better interaction with the
target enzyme, has compromised the ability to cross the parasite
membrane, likely due to a reduced aﬃnity for membrane
Figure 4. (a) Two possible binding modes of 16 within TbFolD as resulted from docking studies. FolD is shown using the same color scheme
employed in Figure 3. The ligand C atoms are represented as white sticks. (b) Binding modes of 18 within TbFolD.
Figure 5. Superimposition of the human FolD (PDB code 1DIG)5
and TbFolD/2 (PDB 4LRR) complexes, represented as green and
orange ribbons and sticks, respectively. Nonconserved residues
between the two species are labeled. The NADP+ cofactor and
water molecules were removed for clarity. This picture was obtained
using Chimera software (UCSF).14
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transporters. Indeed, very little modiﬁcation of the Glu chain,
such as the one carbon homologation of compound 2 leading
to 16, has produced a complete loss of antiparasitic activity.
This suggests that, to obtain more eﬃcacious analogues, also
the interaction with membrane transporters should be
considered at the onset of the design process.
■ EXPERIMENTAL SECTION
Material and Methods. All reagents were purchased from Sigma.
1H NMR and 13C NMR spectra were recorded with a Varian Mercury
300 (300 MHz) spectrometer. Chemical shifts (δ) are expressed in
ppm, and coupling constants (J) are expressed in Hz. TLC analyses
were performed on commercial silica gel 60 F254 aluminum sheets;
spots were further evidenced by spraying with a dilute alkaline
potassium permanganate solution or ninhydrin. Melting points were
determined on a model B 540 Büchi apparatus and are uncorrected.
Mass spectrometry was carried out on a triple quadrupole
spectrometer type Varian 320-MS coupled with ESI source. Elemental
analyses were performed on a PerkinElmer PE 2400 elemental
analyzer, and the data for C, H, and N were within 0.4% of the
theoretical values. All target compounds possessed a purity of ≥95% as
veriﬁed by elemental analyses by comparison with the theoretical
values. (S)-2-Aminoadipic acid dimethyl ester hydrochloride 6 was
synthesized as previously described.11
Synthesis of Ethyl 4-(3-(2,4-diamino-6-oxo-1,6-dihydropyr-
imidin-5-yl)ureido)benzoate (3). 4-Hydroxy-2,5,6-triaminopyrimi-
dine sulfate (0.91 g, 3.8 mmol) was suspended in water (2 mL) and
mixed with a 1 N NaOH solution (11.4 mL). A solution of ethyl 4-
isocyanatobenzoate (0.73 mg, 3.8 mmol) in 6 mL of acetonitrile was
added dropwise. After stirring at room temperature for 2.5 h, 1 N HCl
(11.4 mL) was added, and the mixture was stirred for 5 min. The solid
was ﬁltered oﬀ and washed with water (50 mL), EtOH (30 mL), and
diethyl ether (30 mL). After drying, the product was obtained as a pale
orange solid (0.95 g, 2.86 mmol, 75% yield). M.p.: dec >180 °C. 1H
NMR (300 MHz, DMSO-d6) δ (ppm): 10.0 (bs, 1H, -NHCONH-),
8.98 (bs, 1H, -NHCONH−), 7.84 (d, 2H, J = 8.4, Ar−H), 7.57 (d, 2H,
J = 8.4, Ar−H), 6.76 (s, 1H, -NH−), 6.16 (bs, 2H, -NH2), 5.96 (bs,
2H, -NH2), 4.26 (q, 2H, J = 7.0, CH2CH3), 1.31 (t, 3H, J = 7.0,
CH2CH3).
13C NMR (75 MHz, DMSO-d6) δ (ppm): 166.22, 162.38,
160.97, 155.26, 154.02, 145.89, 130.89, 122.60, 117.61, 89.94, 60.85,
14.94. MS: 333.0 [M + H]+. Anal. Calcd for C14H16N6O4: C 50.60, H
4.85, N 25.29; found, C 50.62, H 4.98, N 25.03.
Synthesis of 4-(3-(2,4-Diamino-6-oxo-1,6-dihydropyrimidin-
5-yl)ureido)benzoic Acid (4). Compound 3 (0.95 g, 2.86 mmol)
was suspended in water (25 mL), and 1 N NaOH (29 mL) was added.
The mixture was stirred at room temperature for 3 h, and it slowly
turned into a clear solution. 1 N HCl (29 mL) was added, and the
precipitate was collected by centrifugation (5000 rpm for 3 min). The
solid was sequentially washed and centrifuged (5000 rpm for 3 min)
with water (20 mL), EtOH (20 mL), and diethyl ether (20 mL). The
product was collected as a pale orange solid (0.80 g, 2.63 mmol, 92%
yield). M.p.: dec T > 240 °C. 1H NMR (300 MHz, DMSO-d6) δ
(ppm): 12.50 (bs, 1H, COOH), 9.98 (bs, 1H, -NHCONH-), 8.90 (bs,
1H, -NHCONH−), 7.80 (d, 2H, J = 7.6, Ar−H), 7.52 (d. 2H, J = 7.6,
Ar−H), 6.71 (s, 1H, -NH−), 6.18 (bs, 2H, -NH2), 5.88 (bs, 2H,
-NH2).
13C NMR (75 MHz, DMSO-d6) δ (ppm): 167.81, 162.20,
160.88, 155.26, 153.98, 145.58, 131.07, 123.50, 117.49, 90.05. MS:
305.0 [M + H]+. Anal. Calcd for C12H12N6O4: C 47.37, H 3.98, N
27.62; found, C 47.41, H 4.06, N 27.40.
General Procedure for the Synthesis of 5 and Analogues
11−15. A suspension of compound 4 (0.1 g, 0.33 mmol) in dry DMF
(7 mL) was placed under a nitrogen atmosphere and sonicated for 5
min. N-Methylmorpholine (0.146 mL, 1.32 mmol) was added to the
mixture, followed by 2-chloro-4,6-dimethoxy-1,3,5-triazine (232 mg,
1.32 mmol), and the mixture was stirred at 35 °C under nitrogen for 5
h. The suspension slowly turned into an orange-red solution. The
desired amino acid (6−10) as methyl or ethyl ester hydrochloride
(1.32 mmol) was added to the solution followed by N-methylmorpho-
line (0.146 mL, 1.32 mmol), and the mixture was stirred at 30 °C
overnight. The solvent was removed under vacuum, keeping the
temperature below 45 °C, and the crude mixture was resuspended in
EtOH (10 mL) and stirred for 5 min. The solid was recovered by
vacuum ﬁltration and washed with EtOH (10 mL) and diethyl ether
(10 mL) and ﬁnally dried under vacuum overnight.
(S)-Diethyl 2-(4-(3-(2,4-diamino-6-oxo-1,6-dihydropyrimi-
din-5-yl)ureido)benz amido) Pentanedioate (5). Pale orange
solid; yield, 70%; m.p., dec T > 180 °C. 1H NMR (300 MHz, DMSO-
d6) δ (ppm): 9.95 (bs, 1H, -NHCONH-), 8.82 (bs, 1H,
-NHCONH−), 8.48 (d, 1H, J = 7.0, ArCO-NH-), 7.80 (d, 2H, J =
8.8, Ar−H), 7.50 (d, 2H, J = 8.8, Ar−H), 6.70 (s, 1H, -NH−), 6.18
(bs, 2H, -NH2), 5.88 (bs, 2H, -NH2), 4.40−4.37 (m, 1H, Hα), 4.07 (q,
2H, J = 7.3, CH2CH3), 4.00 (q, 2H, J = 7.3, CH2CH3), 2.45−2.38 (m,
2H, CH2CH2COOEt), 2.17−1.95 (m, 2H, CHCH2CH2COOEt), 1.17
(t, 3H, J = 7.3, CH2CH3), 1.13 (t, 3H, J = 7.3, CH2CH3).
13C NMR
(75 MHz, DMSO-d6) δ (ppm): 172.92, 172.66, 166.98, 162.17,
160.88, 155.37, 153.95, 144.36, 129.06, 126.59, 117.37, 90.10, 61.17,
60.60, 52.65, 30.91, 26.46, 14.76; MS 490.2 [M + H]+. Anal. Calcd for
C21H27N7O7: C 51.53, H 5.56, N 20.03; found, C 51.61, H 5.60, N
19.91.
(S)-Dimethyl 2-(4-(3-(2,4-diamino-6-hydroxypyrimidin-5-yl)-
ureido)benzamido)hexanedioate (11). Pale orange solid; yield,
61%; m.p., dec T > 190 °C. 1H NMR (300 MHz, DMSO-d6) 9.96 (bs,
1H, CONHAr), 8.82 (bs, 1H, Pyrim-NHCO), 8.50 (d, 1H, J = 7.4,
CONHCα), 7.77 (d, 2H, J = 8.8, Ar−H), 7.50 (d, 2H, J = 8.8, Ar−H),
6.69 (s, 1H, OH), 6.14 (bs, 2H, -NH2), 5.88 (bs, 2H, -NH2), 4.38 (dt,
1H, J = 6.9, 7.4, Hα), 3.62 (s, 3H, OCH3), 3.56 (s, 3H, OCH3), 2.32
(t, 2H, J = 7.3, CH2CH2CH2COOMe), 1.89−1.72 (m, 2H,
CH2CH2CH2COOMe), 1.68−1.53 (m, 2H, CH2CH2CH2COOCH3).
13C NMR (75 MHz, DMSO-d6) 173.76, 173.45, 166.88, 162.29,
160.88, 155.37, 153.97, 144.37, 129.07, 126.53, 117.34, 90.05, 53.00,
52.51, 51.94, 33.46, 30.51, 22.00. MS 476.2 m/z [M + H]+. Anal. Calcd
for C20H25N7O7: C 50.52; H 5.30; N 20.62; found, C 50.62, H 5.58, N
20.43.
(S)-Methyl 2-(4-(3-(2,4-diamino-6-hydroxypyrimidin-5-yl)-
ureido)benzamido)propanoate (12). Pale orange solid; yield,
69%; m.p., dec T > 182 °C. 1H NMR (300 MHz, DMSO-d6) 9.98 (bs,
1H, CONHAr), 8.82 (bs, 1H, Pyrim-NHCO), 8.55 (d, 1H, J = 6.9,
CONHCα), 7.77 (d, 2H, J = 8.7, Ar−H), 7.50 (d, 2H, J = 8.7, Ar−H),
6.70 (s, 1H, OH), 6.17 (bs, 2H, -NH2), 5.89 (bs, 2H, -NH2), 4.43 (dq,
1H, J = 6.9, 7.1, Hα), 3.62 (s, 3H, OCH3), 1.37 (d, 3H, J = 7.1,
CHCH3).
13C NMR (75 MHz, DMSO-d6) 174.08, 166.52, 162.20,
160.88, 155.37, 153.95, 144.33, 129.03, 126.52, 117.31, 90.03, 52.50,
48.86, 17.49. MS 390.1 m/z [M + H]+. Anal. Calcd for C16H19N7O5: C
49.35; H 4.92; N 25.18; found, C 49.38, H 4.95, N 24.98.
(S)-Methyl 2-(4-(3-(2,4-diamino-6-hydroxypyrimidin-5-yl)-
ureido)benzamido)-3-phenylpropanoate (13). Pale orange
solid; yield, 58%; m.p., dec T > 170 °C. 1H NMR (300 MHz,
DMSO-d6) 9.98 (bs, 1H, CONHAr), 8.81 (bs, 1H, Pyrim-NHCO),
8.61 (d, 1H, J = 7.0, CONHCα), 7.70 (d, 2H, J = 8.8, Ar−H), 7.48 (d,
2H, J = 8.8, Ar−H), 7.30−7.21 (m, 4H, CH2−C6H5), 7.20−7.13 (m,
1H, CH2−C6H5), 6.70 (s, 1H, OH), 6.16 (bs, 2H, -NH2), 5.89 (bs,
2H, -NH2), 4.60 (ddd, 1H, J = 6.0, 8.0, 9.1, Hα), 3.61 (s, 3H, OCH3)
3.17−3.04 (m, 2H, J = 7.3, CH2-C6H5). 13C NMR (75 MHz, DMSO-
d6) 173.11, 166.74, 162.27, 160.87, 155.35, 153.96, 144.36, 138.49,
129.74, 128.99, 128.93, 127.15, 126.48, 117.34, 90.05, 54.71, 52.57,
36.97. MS 466.2 m/z [M + H]+. Anal. Calcd for C22H23N7O5: C
56.77; H 4.98; N 21.06; found, C 56.96, H 5.18, N 20.82.
(S)-Methyl 2-(4-(3-(2,4-diamino-6-hydroxypyrimidin-5-yl)-
ureido)benzamido)-3-(4-hydroxyphenyl) propanoate (14).
Pale orange solid; yield, 59%; m.p., dec T > 175 °C. 1H NMR (300
MHz, DMSO-d6) 9.97 (bs, 1H, CONHAr), 9.19 (s, 1H, CH2−
C6H4OH), 8.83 (bs, 1H, Pyrim-NHCO), 8.55 (d, 1H, J = 7.8,
CONHCα), 7.70 (d, 2H, J = 8.7, Ar−H), 7.48 (d, 2H, J = 8.7, Ar−H),
7.06 (d, 2H, J = 8.4, CH2−C6H4OH), 6.71 (s, 1H, OH), 6.63 (d, 2H, J
= 8.4, CH2−C6H4OH), 6.15 (bs, 2H, -NH2), 5.89 (bs, 2H, -NH2),
4.56−4.45 (m, 1H, Hα), 3.60 (s, 3H, OCH3), 3.05−2.87 (m, 2H,
CH2C6H4OH).
13C NMR (75 MHz, DMSO-d6) 173.26, 166.73,
162.31, 160.89, 156.58, 155.36, 153.97, 144.34, 130.67, 129.00, 128.43,
126.53, 117.30, 115.71, 90.03, 55.37, 52.49, 36.26. MS 482.2 m/z [M +
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H]+. Anal. Calcd for C22H23N7O6: C 54.88; H 4.82; N 20.36; found, C,
54.97; H, 4.97; N, 20.01.
Methyl 4-(4-(3-(2,4-diamino-6-hydroxypyrimidin-5-yl)-
ureido)benzamido)butanoate (15). Pale orange solid; yield, 63%;
m.p., dec T > 210 °C; 1H NMR (300 MHz, DMSO-d6) 9.98 (bs, 1H,
CONHAr), 8.77 (bs, 1H, Pyrim-NHCO), 8.26 (t, 1H, J = 5.5,
CONHCH2), 7.71 (d, 2H, J = 8.5, Ar−H), 7.47 (d, 2H, J = 8.5, Ar−
H), 6.69 (s, 1H, OH), 6.16 (bs, 2H, -NH2), 5.88 (bs, 2H, -NH2), 3.56
(s, 3H, OCH3), 3.23 (dt, 2H, J = 5.5, 6.6, CH2CH2CH2COOMe), 2.34
(t, 2H, J = 7.1, CH2CH2CH2COOMe), 1.75 (tt, 2H, J = 6.6, 7.1,
CH2CH2CH2COOMe).
13C NMR (75 MHz, DMSO-d6) 173.88,
166.57, 162.28, 160.88, 155.39, 153.96, 143.94, 128.65, 127.49, 117.36,
90.11, 51.92, 39.09, 31.53, 25.28. MS 404.2 m/z [M + H]+. Anal. Calcd
for C17H21N7O5: C 50.62; H 5.25; N 24.31; found, C 50.52, H 5.38, N
24.33.
General Procedure for the Synthesis of 2 and Analogues
16−20. Compound 5 (or analogues 11−15) (0.2 mmol) was
dissolved in 1 N NaOH (0.8 mmol), and the solution was stirred at
room temperature for 5 h. The solution was neutralized with 1 N HCl,
and the precipitate was recovered by vacuum ﬁltration and washed
with water (10 mL), EtOH (20 mL), and diethyl ether (20 mL) and
ﬁnally dried under vacuum overnight.
(S)-2-(4-(3-(2,4-Diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-
ureido)benzamido)pentanedioic Acid (2). Pale orange solid;
yield, 88%; m.p., dec T > 190 °C. 1H NMR (300 MHz, DMSO-d6)
δ (ppm): 12.35 (bs, 1H, COOH), 9.98 (bs, 1H, -NHCONH-), 8.82
(bs, 1H, -NHCONH−), 8.38 (d, 1H, J = 6.6, ArCO-NH-), 7.79 (d,
2H, J = 8.0, Ar−H), 7.50 (d. 2H, J = 8.0, Ar−H), 6.68 (s, 1H, -NH−),
6.18 (bs, 2H, -NH2), 5.90 (bs, 2H, -NH2), 4.40−4.30 (m, 1H, Hα),
2.38−2.30 (m, 2H, CH2CH2COOH), 2.10−2.00 (m, 1H,
CHCH2CH2COOH), 2.00−1.90 (m, 1H, CHCH2CH2COOH). 13C
NMR (75 MHz, DMSO-d6) δ (ppm): 174.58, 174.28, 166.85, 162.30,
160.90, 155.39, 153.98, 144.26, 129.01, 126.82, 117.36, 90.10, 52.55,
31.15, 26.68. MS: 434.1 [M + H]+. Anal. Calcd for C17H19N7O7: C
47.11, H 4.42, N 22.62; found, C 47.20, H 4.50, N 22.46.
(S)-2-(4-(3-(2,4-diamino-6-hydroxypyrimidin-5-yl)ureido)-
benzamido)hexanedioic Acid (16). Pale orange solid; yield, 78%;
m.p., dec T > 205 °C. 1H NMR (300 MHz, d6-DMSO) 12.26 (bs, 2H,
COOH), 9.97 (bs, 1H, CONHAr), 8.80 (bs, 1H, Pyrim-NHCO), 8.35
(d, 1H, J = 7.7, CONHCα), 7.78 (d, 2H, J = 8.7, Ar−H), 7.50 (d, 2H,
J = 8.7, Ar−H), 6.69 (s, 1H, OH), 6.14 (bs, 2H, -NH2), 5.87 (bs, 2H,
-NH2), 4.31 (dt, 1H, J = 5.1, 7.7, Hα), 2.22 (t, 2H, J = 7.4,
CH2CH2CH2COOH), 1.89−1.68 (m, 2H, CH2CH2CH2COOH),
1.68−1.49 (m, 2H, CH2CH2CH2COOCH3). 13C NMR (75 MHz,
d6-DMSO) 174.96, 174.54, 166.69, 162.27, 160.90, 155.38, 153.99,
144.21, 128.97, 126.95, 117.35, 90.14, 53.09, 33.97, 30.90, 22.15. MS
448.1 m/z [M + H]+. Anal. Calcd for C18H21N7O7: C 48.32; H 4.73; N
21.91; found, C 48.42, H 4.90, N 21.63.
(S)-2-(4-(3-(2,4-Diamino-6-hydroxypyrimidin-5-yl)ureido)-
benzamido)propanoic Acid (17). Pale orange solid; yield, 70%;
m.p., dec T > 195 °C. 1H NMR (300 MHz, DMSO-d6) 12.44 (bs, 1H,
COOH), 9.98 (bs, 1H, CONHAr), 8.82 (bs, 1H, Pyrim-NHCO), 8.40
(d, 1H, J = 7.1, CONHCα), 7.77 (d, 2H, J = 8.8, Ar−H), 7.49 (d, 2H,
J = 8.8, Ar−H), 6.69 (s, 1H, OH), 6.13 (bs, 2H, -NH2), 5.87 (bs, 2H,
-NH2), 5.74 (s, 1H, OH), 4.37 (dq, 1H, J = 7.1, 7.4, Hα), 1.36 (d, 3H,
J = 7.4, CHCH3).
13C NMR (75 MHz, DMSO-d6) 175.15, 166.33,
162.32, 160.90, 155.40, 153.99, 144.19, 128.94, 126.88, 117.33, 90.07,
48.85, 17.8. MS 376.1 m/z [M + H]+. Anal. Calcd for C15H17N7O5: C
48.00; H 4.57; N 26.12; found, C 47.84, H 4.78, N 25.93.
(S)-2-(4-(3-(2,4-Diamino-6-hydroxypyrimidin-5-yl)ureido)-
benzamido)-3-phenylpropanoic Acid (18). Pale orange solid;
yield, 72%; m.p., dec T > 180 °C. 1H NMR (300 MHz, DMSO-d6)
12.76 (bs, 1H, COOH), 9.97 (bs, 1H, CONHAr), 8.79 (bs, 1H,
Pyrim-NHCO), 8.46 (d, 1H, J = 8.2, CONHCα), 7.69 (d, 2H, J = 8.8,
Ar−H), 7.48 (d, 2H, J = 8.8, Ar−H), 7.33−7.21 (m, 4H, CH2−C6H5),
7.19−7.12 (m, 1H, CH2−C6H5), 6.69 (s, 1H, OH), 6.14 (bs, 2H,
-NH2), 5.87 (bs, 2H, -NH2), 4.56 (ddd, 1H, J = 4.6, 8.2, 10.5, Hα),
3.15 (dd, 1H, J = 4.6, 13.8, CH2-C6H5), 3.04 (dd, 1H, J = 10.5, 13.8,
CH2-C6H5).
13C NMR (75 MHz, DMSO-d6) 174.09, 166.64, 162.27,
160.88, 155.35, 153.97, 144.22, 138.99, 129.74, 128.91, 128.85, 126.99,
126.81, 117.33, 90.08, 54.88, 37.01. MS 452.2 m/z [M + H]+. Anal.
Calcd for C21H21N7O5: C 55.87; H 4.69; N 21.72; found, C 55.57, H
4.94, N 21.52.
(S)-2-(4-(3-(2,4-Diamino-6-hydroxypyrimidin-5-yl)ureido)-
benzamido)-3-(4-hydroxyphenyl)propanoic Acid (19). Pale
orange solid; yield: 76%; m.p.: dec T > 198 °C; 1H NMR (300
MHz, DMSO-d6) 12.61 (bs, 1H, COOH), 9.96 (bs, 1H, CONHAr),
9.16 (s, 1H, CH2−C6H4OH), 8.81 (bs, 1H, Pyrim-NHCO), 8.39 (d,
1H, J = 8.2, CONHCα), 7.69 (d, 2H, J = 8.8, Ar−H), 7.47 (d, 2H, J =
8.8, Ar−H), 7.07 (d, 2H, J = 8.4, CH2−C6H4OH), 6.69 (s, 1H, OH),
6.62 (d, 2H, J = 8.4, CH2−C6H4OH), 6.15 (bs, 2H, -NH2), 5.89 (bs,
2H, -NH2), 4.53−4.41 (m, 1H, Hα), 3.02 (dd, 1H, J = 4.5, 13.8, CH2-
C6H4OH), 2.91 (dd, 1H, J = 10.1, 13.8, CH2-C6H4OH);
13C NMR
(75 MHz, DMSO-d6) 174.24, 166.64, 162.27, 160.88, 156.48, 155.37,
153.96, 144.21, 130.66, 128.94, 126.86, 126.81, 117.32, 115.65, 90.03,
55.24, 36.25. MS 468.2 m/z [M + H]+. Anal. Calcd for C21H21N7O6: C
53.96; H 4.53; N 20.98; found, C 54.12, H 4.78, N 20.64.
4-(4-(3-(2,4-Diamino-6-hydroxypyrimidin-5-yl)ureido)-
benzamido)butanoic Acid (20). Pale orange solid; yield, 79%; m.p.,
dec T > 230 °C. 1H NMR (300 MHz, DMSO-d6) 12.02 (bs, 1H,
COOH), 9.97 (bs, 1H, CONHAr), 8.78 (bs, 1H, Pyrim-NHCO), 8.25
(t, 1H, J = 5.8, CONHCH2), 7.72 (d, 2H, J = 8.8, Ar−H), 7.47 (d, 2H,
J = 8.8, Ar−H), 6.68 (s, 1H, OH), 6.13 (bs, 2H, -NH2), 5.86 (bs, 2H,
-NH2), 3.23 (dt, 2H, J = 5.8, 6.6, CH2CH2CH2COOH), 2.25 (t, 2H, J
= 7.4, CH2CH2CH2COOH), 1.72 (tt, 2H, J = 5.8, 6.6,
CH2CH2CH2COOH).
13C NMR (75 MHz, DMSO-d6) 174.99,
166.56, 162.25, 160.88, 155.39, 153.96, 143.92, 128.64, 127.57,
117.37, 90.16, 39.24, 31.94, 25.36. MS 390.1 m/z [M + H]+. Anal.
Calcd for C16H19N7O5: C 49.35; H 4.92; N 25.18; found, C 49.32, H
4.78, N 25.02.
Molecular Docking. With the aim to test the Glide 5.5 program
for its ability to reproduce the crystallized binding geometry of 2, the
latter ligand was subjected to automated docking calculations using
extra precision (XP) mode and Glidescore for ligand ranking.12,13
Before docking, water molecules were removed, while the NADP+
cofactor was retained. The program was successful in reproducing the
experimentally found binding mode of 2, as it corresponds to the best
ranked solution with an RMSD of only 0.87 Å. The binding modes of
compounds 16 and 18 were accordingly investigated. The herein
reported X-ray structure of TbFolD was prepared through the Protein
Preparation Wizard within the Maestro 9.0.2112 package using the
OPLS-2001 force ﬁeld. Figures were rendered using the Chimera
software package.14
Single Crystal X-ray Diﬀraction Analysis of 3. Compound 3 is
poorly soluble in most organic solvents at room temperature, with the
exception of DMSO. We therefore tried to grow crystals from DMSO
(in diﬀerent conditions) and from mixtures of DMSO/CH3CN.
Eventually, crystallization by slow evaporation (16 days) of a solution
of 3 in reagent-grade DMSO (Sigma-Aldrich) at room temperature
produced small plates suitable for the determination of the molecular
connectivity. After testing several samples, a specimen (0.25 × 0.20 ×
0.05 mm3) grown at the liquor/air interface was selected for the
crystallographic analysis. The specimen manifested a signiﬁcant
pleochroism (colorless to violet) under polarized light. It was
mounted on the top of a glass capillary ﬁber in dense perﬂuorinated
oil. The X-ray data collection was performed at room temperature on a
3-circle Bruker SMART APEX goniometer equipped with a CCD
APEX-II detector, using graphite-monochromated Mo Kα radiation (λ
= 0.71073 Å). A total of 26180 reﬂections (8144 unique) were
recorded up to (sin ϑ/λ)MAX = 0.5017 Å
−1. A high exposure time (120
s/frame) was employed due to the small dimensions of the sample and
its very low scattering power. The compound was found to crystallize
in the triclinic centrosymmetric P1 ̅ space group (no. 2), with unit cell
parameters a = 8.0260(16) Å, b = 10.054(2) Å, c = 48.956(10) Å, α =
84.44(3)°, β = 89.13(3)°, γ = 80.14(3)°, and V = 3873.8(14) Å3.
Careful visual inspection of the reciprocal lattice showed some weak
oﬀ-lattice spots attributable to a minor non- merohedral epitaxial twin
component of the same 3 phase. Experimental structure factor
amplitudes were extracted by integration of the diﬀraction frames
through the SAINT+ program suite,15 taking into account the
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presence of the additional lattice. Corrections for sample absorption
and X-ray beam anisotropy were applied by the program TWINABS.16
Eventually, the molecular structure was solved and reﬁned with the
SHELX program package.17 In the ﬁnal least-squares reﬁned model,
the nonmerohedral twinning was explicitly accounted for, and the
fractional contribution of the minority component was estimated to be
0.161(3). All of the hydrogen atoms in the asymmetric unit were
idealized, and their coordinates were indirectly determined through a
“riding motion” constraint. Moreover, all the bonds involving non-H
atoms were subjected to a “rigid-bond” restraint, i.e., the component of
the atomic anisotropic displacement parameters along the bond
direction were restrained to be equal within a tolerance of 0.01 Å2.
This strategy was motivated by (i) the rather poor quality of the
sample and, consequently, the relatively low maximum resolution
available for the data; (ii) the quite low data-to-parameter ratio (≈ 8),
due to the high number of symmetry-unrelated molecules in a large
unit cell. However, these drawbacks did not hamper us from reliably
determining the molecular connectivity of 3, even though our
estimates for bond distances and angles have, on average, a rather
low precision. CCDC 973826 contains the supplementary crystallo-
graphic data for this work. The latter can be obtained free of charge
from the Cambridge Crystallographic Data Centre via www.ccdc.cam.
ac.uk/data_request/cif.
Preparation of a Recombinant Expression System and
Puriﬁcation of TbFolD. The gene encoding 5,10-methylene
tetrahydrofolate dehydrogenase/5,10 methenyl tetrahydrofolate cyclo-
hydrolase (dhch1) was identiﬁed in Genedb (http://www.genedb.org,
accession number Tb927.7.1600). Genomic DNA from T. brucei
(Lister 927 strain) was used as template for PCR with the following
primers designed to amplify the DHCH1 open reading frame using
NdeI and Xho1 restriction sites (bold), respectively: 5′-CAT-ATG-
CCT-GAG-GCG-GTT-G-3′ and 5′-CTC-GAG-TCA-CAA-GGC-
ACG-AA-3′. The PCR product was inserted into pCR-BluntII-
TOPO vector using the Zero Blunt TOPO PCR cloning kit
(Invitrogen) prior to excision and ligation into a modiﬁed pET15b
vector (Novagen) containing a tobacco etch virus (TEV) protease
recognition sequence (pET15bTEV). This results in recombinant
expression of a product carrying an N-terminal hexa-histidine tag (His-
tag), which is cleavable with TEV protease. The recombinant plasmid
was ampliﬁed in XL-1 blue E. coli, and the gene sequence veriﬁed by
DNA sequencing services (Dundee University), before being trans-
formed into E. coli BL21 (DE3) for protein production.
Protein was produced in cells cultured at 37 °C in 1 L LB media
containing 50 mg/mL ampicillin. When an OD of 0.8 was attained,
expression was induced with IPTG (1 mM) for 16 h at 21 °C. Cells
were collected by centrifugation at 4000 rpm for 30 min at 4 °C and
frozen at −80 °C until required. After thawing, the cells were
resuspended in 50 mM bicine and 50 mM NaCl, pH 8.0 (using 2 mL/
g pellet), with the addition of Complete (Roche EDTA-free protease
inhibitor) then lysed by sonication (7× 10 s bursts), with cooling to
<4 °C between pulses. The lysate was clariﬁed with centrifugation
(40000g, 30 min, 4 °C). The supernatant was loaded, at 2 mL min−1,
onto a HisTrap HP mL column (prepacked with Ni2+ Sepharose High
Performance-GE Healthcare) equilibrated with buﬀer 50 mM bicine
and 50 mM NaCl, pH 8.0. Unbound protein was removed by washing
with 50 mL of this buﬀer. Retained proteins were eluted with a linear
gradient at 1 mL min−1 of 0−100% of buﬀer 50 mM bicine, 50 mM
NaCl, and 1 M imidazole, pH 8.0. The sample of TbFolD was passed
through a HiTrap Desalting (GE Healthcare) column to exchange the
buﬀer with 50 mM bicine, 250 mM NaCl, 0.5 mM DTT, and 10%
glycerol, pH 8.0. The typical yield of protein was approximately 7 mg/
L of cell culture. The addition of 10% glycerol in all buﬀers was
required to prevent the loss of activity when the samples were ﬂash-
frozen.
Crystallographic Analysis of TbFolD Complexed with
Compound 2. Crystallization trials were carried out with a Phoenix
Liquid Handling System (Art Robbins Instruments/Rigaku) using
commercially available screens (Hampton Research) with a 1:1 ratio of
100 nL of protein solution and an equivalent volume of reservoir
equilibrated against a 70 μL reservoir at 20 °C. Crystals, small
orthorhombic blocks with approximate dimensions of 0.1 × 0.1 × 0.1
mm3, were observed after 3 days in conditions with 20% PEG 6000
and 0.1 M citric acid, pH 5.0. We were unable to increase the size of
the crystals using hanging drop or sitting drop vapor diﬀusion
methods. Crystals were transferred into a cryo-solution containing the
reservoir supplemented with 20% glycerol prior to ﬂash freezing at
−173 °C. Crystals were characterized in-house with a Micromax-007
rotating anode generator and R-AXIS IV+2 dual image plate detector
(Rigaku), prior to storage in liquid nitrogen. X-ray diﬀraction data
were then collected on the microfocus beamline of ID23-2 at the
European Synchrotron Radiation Facility (ESRF). Integration and
scaling of data were carried out using MOSFLM18 and SCALA.19 The
crystals belonged to the orthorhombic space group P212121 with unit
cell parameters a = 58.22 Å, b = 77.33 Å, c = 128.91 Å, α = β = γ = 90°.
The molecular weight of a subunit is 31.9 kDa, and the asymmetric
unit consists of two subunits with a VM value of 2.79 Å
3 Da1− and
solvent content of approximately 55%. Statistics are summarized in
Table S3.
The structure of TbFolD was solved by molecular replacement and
reﬁned to a resolution of 2.05 Å. The search model was a monomer of
the L. major FolD structure, which shares a sequence identity of 85%
(PDB code A26),8 with side chains removed. The rotation and
translation functions were determined with PHASER20 with a log
likelihood gain of 84. Inspection of the solution in the graphics
program COOT21 showed that a dimer, consistent with gel ﬁltration
data, was indeed present. Rigid-body reﬁnement was carried out in
REFMAC5.22 Side chains were built into electron and diﬀerence
density maps, followed by iterative rounds of restrained reﬁnement,
model manipulation, and addition of solvent molecules using COOT
and REFMAC5. The ﬁnal model has Rwork and Rfree values of 20% and
24%, respectively. Geometric restrained parameters were manually
adjusted and applied in addition to translation/libration/screw analysis
(TLS)23 during the latter stages of reﬁnement. Model quality was
checked using MolProbity.24 Structure superpositions were calculated
using LSQKAB,25 and ﬁgures were prepared using PyMOL
(Schrödinger LLC).
Enzyme Inhibition Assay. The dehydrogenase activity of FolD
was measured spectrophotometrically, using a Beckman DU-640
spectrophotometer, following the formation of 5,10-CHTHF from
5,10-CH2-THF. 5,10-CH2-THF dehydrogenase assays were carried
out in a 0.5 mL volume at 27 °C and contained 25 mM MOPS, pH
7.3, 30 mM 2-mercaptoethanol, 35 μM mTHF, and 1 mM NADP+.
The Km values of substrate and cofactor having been previously
elucidated as approximately 35 and 70 μM. The reaction was initiated
by the addition of NADP+ and incubated for 5 min then stopped by
the addition of an equal volume of 1 M HCl and the 5,10-CHTHF
produced quantiﬁed at 350 nm, using an extinction coeﬃcient of 24.9
mM−1 cm−1. The enzyme activity was expressed as μ moles 5,10-
CHTHF produced per minute. Enzyme inhibition was measured
using the dehydrogenase assay, with stocks of compounds dissolved in
DMSO (10 mM). The concentration of compound in the ﬁrst test was
0−50−100 μM. Data from inhibition assays were ﬁtted to a
competitive model by linear regression using Origin (OriginLab
Corporation).
Cellular Studies. Trypanosome Culture. The bloodstream-form
T. brucei brucei strain 427 was grown in HMI-9 medium −17.66 mg/
mL IMDM (Gibco), 3.020 mg/mL sodium bicarbonate (Sigma-
Aldrich), 0.136 mg/mL hypoxanthine (Sigma-Aldrich), 0.039 mg/mL
thymidine (Sigma-Aldrich), and 0.028 mg/mL bathocuproine sulfonic
acid (Sigma-Aldrich) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) (BioWhittaker), 1.5 mM L-cysteine hydrochloride
monohydrate (Merck), 0.2 mM β-mercaptoethanol (Sigma-Aldrich),
100 U/mL penicillin, and 100 U/mL streptomycin (BioWhittaker) at
37 °C under a humidiﬁed 5% CO2 atmosphere. Cultures were grown
in T25 or T75 vented cap culture ﬂasks (Sarstedt) and subcultured
every 2−3 days by 100- to 1000-fold dilution, respectively. Parasites
were counted directly using a Neubauer chamber (Marienfeld) and
diluted appropriately in complete HMI-9 medium.
In Vitro Growth Inhibition Assays. The compounds under study
and 21 were tested in a serial drug dilution assay in order to determine
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the IC50 values (concentration of drug causing 50% growth inhibition)
by using the Alamar Blue assay.26 Serial drug dilutions were prepared
in 96-well microtiter plates containing culture medium as described
above, and wells were inoculated with approximately 2,000 blood-
stream form T. b. brucei cells. Cultures were incubated for 72 h at 37
°C under a humidiﬁed 5% CO2 atmosphere. After this time, resazurin
was added to a concentration of 45.5 μM per well. The plates were
incubated for an additional 4 h, and then the ﬂuorescence read in a
microplate reader (Sinergy 2, BioTek) using an excitation wavelength
of 528 nm and an emission wavelength of 590 nm. The IC50 values
were calculated by linear regression analysis.
Cytotoxicity. The cytotoxicity of the compounds under study was
assessed by a colorimetric MTT assay.26,27 THP1 diﬀerentiated
macrophages were seeded at a density of 105 cells/well in 96-well
plates and allowed to adhere overnight. Cells were incubated with the
compound concentration range for 72 h at 37 °C. At the end of the
incubation period, 200 μL of 0.5 mg/mL MTT reagent (thiazolyl blue
tetrazolium bromide, Sigma) solution was added to each well. The
plates were further incubated for 4 h at 37 °C in the dark. The culture
medium was subsequently discarded, and 200 μL of isopropanol was
added to dissolve the dark-blue formazan crystals. Cell viability was
quantiﬁed spectrophotometrically by measuring the absorbance of the
formazan product at wavelength 570 nm and the background at 660
nm with a microplate reader (Synergy 2, Biotek, USA). The data are
expressed as the percentages of viable cells compared to the survival of
a control group (untreated cells). The IC50 value, i.e., the
concentration of compounds necessary to decrease cell viability to
50% of the untreated control was determined by linear regression
analysis.
Statistical Analysis. Diﬀerences between in vitro anti-Trypanoso-
ma and THP1 cell cytotoxicity were examined using Student’s t test.
The data are presented as the means ± SD, and all experiments were
independently repeated at least three times. p-values <0.05 (two-sided)
were considered to be statistically signiﬁcant.
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